Since the original description of the NPM1-ALK fusion gene in ALCL, a large number of distinct ALK fusion partners have been identified in ALCL as well as a variety of other malignancies including diffuse large B cell lymphoma, inflammatory myofibroblastic tumor, non-small cell lung cancer, and renal cell carcinoma [2, 3]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.